CD8A and neoplasm: Although immune checkpoint blockade (ICB) has revolutionized the treatment of CRC [3], this therapeutic resistance is largely attributed to an immunologically “cold” tumor microenvironment (TME) characterized by poor infiltration of cytotoxic CD8+ T cells and antigen-presenting cells, ultimately facilitating tumor immune escape [4].